Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders
10 avr. 2024 07h17 HE
|
Clearmind Medicine Inc.
Vancouver, Canada, April 10, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "company"), a clinical- stage biotech company focused on discovery and...
Tome Biosciences Announces US Patent Issued for Integrase-Mediated Programmable Genomic Integration
09 avr. 2024 08h08 HE
|
Tome Biosciences
Tome granted US patent for programmable genomic integration.
Anaqua améliore sa plateforme de recherche de brevets AcclaimIP en ajoutant des capacités basées sur l'IA
08 avr. 2024 09h37 HE
|
Anaqua
BOSTON, 08 avr. 2024 (GLOBE NEWSWIRE) -- Anaqua, le leader des technologies de gestion de la propriété intellectuelle (PI) et de l’innovation, continue d'améliorer sa puissante plateforme de...
Anaqua Enhances AcclaimIP Patent Search with AI-Powered Capabilities
08 avr. 2024 09h37 HE
|
Anaqua
Anaqua revolutionizes patent search with AI-powered AcclaimIP. Explore over 100M patents worldwide with user-friendly interface and cutting-edge AI.
Intelligencia AI Awarded U.S. Patent for Its Accurate and Transparent Probability of Drug Success Assessments
02 avr. 2024 13h43 HE
|
Intelligencia AI
Health tech company pioneers de-risking clinical development through patented algorithms, technology and use of artificial intelligence
Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office
27 mars 2024 08h00 HE
|
PharmAla Biotech
PharmAla recieves Allowance from USPTO for its lead drug candidate, a next-generation MDMA composition paving the way for clinical trials
Vidac Pharma receives Japanese Patent Office Notice of Allowance for VDA-1275 cancer drug candidate
27 mars 2024 02h30 HE
|
Vidac Pharma Holding PLC
Vidac Pharma receives Japanese Patent Office Notice of Allowance for VDA-1275 cancer drug candidate London (UK), March 27, 2024 (07:30 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G;...
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
21 mars 2024 21h40 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, March 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and...
Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device
20 mars 2024 16h05 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, March 20, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the U.S. Patent and Trademark...
Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office
20 mars 2024 10h20 HE
|
PharmAla Biotech
PharmAla Recieves Notice of Allowance of Patent on Novel MDMA-like Molecule with improved safety, therapeutic range